Literature DB >> 19630607

Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects.

U Jain, B Birmaher, M Garcia, M Al-Shabbout, N Ryan.   

Abstract

ABSTRACT The charts of 31 hospitalized children and adolescents (ages 9-18 years) with major mood disorders were retrospectively reviewed to examine the efficacy and side effects of treatment with fluoxetine. After treatment for a mean duration of 35 days, clinical improvement was seen in 74% of these patients; 54% had "much" to "very much" improvement as measured by the Clinical Global Impression scale (CGI). The most common adverse effects were hypomania-like symptoms (23%), irritability (19%), gastrointestinal upset (13%), and insomnia (13%). No EKG changes, blood pressure changes, anticholinergic symptoms, sedation, weight changes, or seizures were observed. None of the patients experienced an increase in suicidal or parasuicidal behavior. Discontinuation of the fluoxetine treatment occurred in 28% of cases, most commonly because of increasing irritability and hypomania-like symptoms. The hypomania-like effects included a constant sense of silliness, increased activity, poor sleep, increased energy, an increase in the stream of thoughts (racing thoughts), or socially intrusive or obnoxious behavor. Fluoxetine triggered symptoms suggestive of hypomania in all four of the depressive bipolar patients.

Entities:  

Year:  1992        PMID: 19630607     DOI: 10.1089/cap.1992.2.259

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  9 in total

Review 1.  Pharmacological treatment of depression in children and adolescents.

Authors:  R L Findling; M D Reed; J L Blumer
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

Authors:  Jack R Cornelius; Oscar G Bukstein; Antoine B Douaihy; Duncan B Clark; Tammy A Chung; Dennis C Daley; D Scott Wood; Sandra J Brown
Journal:  Drug Alcohol Depend       Date:  2010-06-23       Impact factor: 4.492

3.  TREATMENT TRIAL AND LONG-TERM FOLLOW-UP EVALUATION AMONG COMORBID YOUTH WITH MAJOR DEPRESSION AND A CANNABIS USE DISORDER.

Authors:  Jack R Cornelius; Ihsan M Salloum; Robert Ferrell; Antoine B Douaihy; Jeanie Hayes; Levent Kirisci; Michelle Horner; Dennis C Daley
Journal:  Int J Med Biol Front       Date:  2012

4.  Fluoxetine Related Urinary Retention in a 15-Year-Old Girl: a Case Report.

Authors:  Ömer Faruk Bulut; Ali Karayağmurlu; İlyas Kaya
Journal:  Noro Psikiyatr Ars       Date:  2022-08-16       Impact factor: 1.066

5.  Efficacy of antidepressants in child and adolescent depression: a meta-analytic study.

Authors:  K Papanikolaou; C Richardson; A Pehlivanidis; Z Papadopoulou-Daifoti
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

6.  Sleep disturbance as detected by actigraphy in pre-pubertal juvenile monkeys receiving therapeutic doses of fluoxetine.

Authors:  Mari S Golub; Casey E Hogrefe
Journal:  Neurotoxicol Teratol       Date:  2016-03-05       Impact factor: 3.763

Review 7.  A risk-benefit assessment of pharmacotherapy for anxiety disorders in children and adolescents.

Authors:  S M Hawkridge; D J Stein
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

8.  Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.

Authors:  Jack R Cornelius; Oscar G Bukstein; D Scott Wood; Levent Kirisci; Antoine Douaihy; Duncan B Clark
Journal:  Addict Behav       Date:  2009-03-12       Impact factor: 3.913

Review 9.  Fluoxetine Administration in Juvenile Monkeys: Implications for Pharmacotherapy in Children.

Authors:  Mari S Golub; Casey E Hogrefe; Richard J Sherwood; Christoph W Turck
Journal:  Front Pediatr       Date:  2018-02-08       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.